Duchenne Muscular Dystrophy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Duchenne Muscular Dystrophy Clinical Trials Market Report Overview
A total of 390 Duchenne muscular dystrophy clinical trials were conducted as of January 2024. The Duchenne Muscular Dystrophy clinical trial report provides a comprehensive understanding of the Duchenne muscular dystrophy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials.
Key Regions | · North America
· Europe · Asia-Pacific · Middle East and Africa · South and Central America |
Key Countries | · The US
· The UK · Canada · Italy · Belgium · France · Australia · Germany · Spain · Japan |
Key Sponsor Types | · Company
· Institution · Government |
Leading Sponsors | · Sarepta Therapeutics Inc
· PTC Therapeutics Inc · BioMarin Pharmaceutical Inc · Nippon Shinyaku Co Ltd · GSK plc · F. Hoffmann-La Roche Ltd · Santhera Pharmaceuticals Holding AG |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Duchenne Muscular Dystrophy Clinical Trials Segmentation by Regions and Countries
As of January 2024, North America led the Duchenne muscular dystrophy clinical trials landscape with more than 35% of the clinical trials conducted there
The key regions considered for Duchenne muscular dystrophy clinical trials analysis are North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.
In the country-wise analysis, the US had the highest number of Duchenne muscular dystrophy clinical trials as of January 2024. France had the highest average patient enrollment in Duchenne muscular dystrophy clinical trials during the same time.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, Italy had the highest proportion of Duchenne Muscular Dystrophy to Genetic Disorders clinical trials as of January 2024.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Turkey had the highest proportion of Duchenne Muscular Dystrophy to Genetic Disorders clinical trials as of January 2024.
Duchenne Muscular Dystrophy Clinical Trials Analysis by Regions, 2024 (%)
Buy the Full Report for More Regional Insights into the Duchenne Muscular Dystrophy Clinical Trials
Duchenne Muscular Dystrophy Clinical Trials Segmentation by Sponsor Types
The key sponsor types for Duchenne muscular dystrophy clinical trials are company, institution, and the government. As of January 2024, more than 62% of Duchenne muscular dystrophy clinical trials conducted were sponsored by company sponsor type, followed by institution.
Duchenne Muscular Dystrophy Clinical Trials Analysis by Sponsor Types, 2024 (%)
Buy the Full Report for More Sponsor Type Insights into the Duchenne Muscular Dystrophy Clinical Trials
Duchenne Muscular Dystrophy Clinical Trials - Competitive Landscape
In 2024, Sarepta Therapeutics Inc. conducted the highest number of Duchenne muscular dystrophy clinical trials
A few of the leading sponsors for Duchenne muscular dystrophy clinical trials are:
- Sarepta Therapeutics Inc.
- PTC Therapeutics Inc.
- BioMarin Pharmaceutical Inc.
- Nippon Shinyaku Co Ltd
- GSK plc
- Hoffmann-La Roche Ltd
- Santhera Pharmaceuticals Holding AG
Duchenne Muscular Dystrophy Clinical Trials Analysis by Sponsors, 2024 (%)
Buy the Full Report to Know More about the Leading Sponsors of Duchenne Muscular Dystrophy Clinical Trials
Segments Covered in the Report
Duchenne Muscular Dystrophy Clinical Trials Regional Outlook (2024)
- North America
- Europe
- Asia-Pacific
- Middle East and Africa
- South and Central America
Duchenne Muscular Dystrophy Clinical Trials Country Outlook (2024)
- The US
- The UK
- Canada
- Italy
- Belgium
- France
- Australia
- Germany
- Spain
- Japan
Duchenne Muscular Dystrophy Clinical Trials Sponsor Type Outlook (2024)
- Company
- Institution
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and endpoint status.
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) of the company.
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with a reason for accomplishment.
- The report provides enrollment trends for the past five years.
- The report provides the latest news for the past three months.
Reasons to Buy
- Formulate key business strategies with regard to investment.
- Identify prominent locations for conducting clinical trials which saves time and cost.
- Get top level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Understand trial count and enrollment trends by country in the global therapeutics market.
- Interpret the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Understand clinical trial assessment of the indication on a global, regional, and country level.
PTC Therapeutics Inc
BioMarin Pharmaceutical Inc
Nippon Shinyaku Co Ltd
GSK plc
F. Hoffmann-La Roche Ltd
Santhera Pharmaceuticals Holding AG
Thermo Fisher Scientific Inc
Astria Therapeutics Inc
Italfarmaco Holding SpA
Table of Contents
Table
Figures
Frequently asked questions
-
Which region accounted for the highest number of Duchenne muscular dystrophy clinical trials in January 2024?
North America accounted for the highest number of Duchenne muscular dystrophy clinical trials as of January 2024.
-
North America accounted for the highest number of Duchenne muscular dystrophy clinical trials as of January 2024.
The US conducted the highest number of Duchenne muscular dystrophy clinical trials as of January 2024.
-
Which sponsor type was the most prominent in the Duchenne muscular dystrophy clinical trials in January 2024?
As of January 2024, most of the Duchenne muscular dystrophy clinical trials conducted were sponsored by company sponsor type.
-
Which are the leading sponsors of Duchenne muscular dystrophy clinical trials?
A few of the leading sponsors of Duchenne muscular dystrophy clinical trials are Sarepta Therapeutics Inc., PTC Therapeutics Inc., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co Ltd, GSK plc, F. Hoffmann-La Roche Ltd, and Santhera Pharmaceuticals Holding AG, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.